business finance

business finance - Submitted by Sherisse Colbourne CBUS 341...

Info iconThis preview shows pages 1–6. Sign up to view the full content.

View Full Document Right Arrow Icon
Submitted by: Sherisse Colbourne CBUS 341 Business Finance T, TR - 10:50am Human Genome Sciences
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
A. COMPANY INFORMATION 1. Human Genome Sciences Inc. 2. Human Genome Sciences , Inc. researches and develops proprietary pharmaceutical and diagnostic products. The Company’s products predict, prevent, detect, treat, and cure disease based on the discovery of human and microbial genes. The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs. The HGS clinical development pipeline includes novel drugs to treat lupus, hepatitis C, inhalation anthrax and cancer. 3. Chairman of the Board: Argeris (Jerry) N. Karabelas CEO/President: H. Thomas Watkins Executive Vice President, General Counsel and Secretary: James H. Davis Executive Vice President and Chief Commercial Officer: Barry A. Labinger Executive Vice President of Growth and Business Development: James P. Southwell Senior Vice President - Human Resources: Susan D. Bateson Senior Vice President, Operations: Curran M. Simpson Vice President, Sales: Scott Habig Vice President, Sales and Marketing: Kevin P. McRaith Vice President, Manufacturing Operations: Randy Maddux 4. Company Standard Industrial Classification Code: 2843 5. Company Stock Symbol: HGSI 6. Stock exchange where the stock is traded: NASDAQ and it’s a common stock. B. FINANCIAL STATEMENT AND STOCK INFORMATION (See Attached)
Background image of page 2
Background image of page 3

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
C. RECENT ARTICLES
Background image of page 4
D. PROJECT REPORT Human Genome Sciences , Inc. researches and develops proprietary pharmaceutical and diagnostic products. The Company’s products predict, prevent, detect, treat, and cure disease based on the discovery of human and microbial genes. The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs. The HGS clinical development pipeline includes novel drugs to treat lupus, hepatitis C, inhalation anthrax and cancer. The Human Genome Services Inc. stock symbol is HGSI, and it’s Standard Industrial Classification (SIC) code is 2843. Human
Background image of page 5

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Image of page 6
This is the end of the preview. Sign up to access the rest of the document.

Page1 / 8

business finance - Submitted by Sherisse Colbourne CBUS 341...

This preview shows document pages 1 - 6. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online